{"name":"MinYoung Kim, M.D.","slug":"minyoung-kim-m-d","ticker":"","exchange":"","domain":"","description":"MinYoung Kim, M.D. is a biotech company focused on innovative therapies, particularly in the early stages of clinical development. The company's lead product is an umbilical cord blood administration therapy currently in Phase 1 trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTFA4ZGpIYlJuNllWY0Z5SGgtM19NeUdCYmRiMFU3NFp0VXJjUzdoaGNOZjBTbDVrSmQxdnJ2YlJWTl9YQnlKQzJTSW9jMkw0ODMxQXZtbHE1eFhvUnFGaTYtbGR3cUo3Qk9IcFNQZFBR?oc=5","date":"2024-01-04","type":"deal","source":"KED Global","summary":"SK Biopharm, Dong-A ST sign licensing deal of Cenobamate - KED Global","headline":"SK Biopharm, Dong-A ST sign licensing deal of Cenobamate","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}